A multicentre retrospective analysis of pre-operative prognostic biomarkers in resected right compared with left colon cancer and the influence of operative approach on survival
IRAS Number: 287131
CPMS ID:
ClinicalTrials.gov ID:
Trial Start Date: Nov-20
Recruitment End Date: Dec-26
Trial End date: Dec-27
A retrospective, non-interventional tissue study using archival materials collected through a patient’s routine care, DRIVEN aims to validate the ctTDV staging system as a prognostic biomarker for use in all colon cancers.
The ctTDV system evaluates the depth of tumour invasion, presence or absence of tumour deposits and/or extramural venous invasion. If DRIVEN is successful in validating ctTDV, this could be used to stratify treatment for patients with right colon cancer with the aim of improving patient outcomes and reducing the disparity in overall survival between those with right sided and left sided colon cancer. Further retrospective tissue analysis on colonoscopic biopsy samples with assessment of other known prognostic biomarkers including the immune score and tumour budding will establish whether or not these too have a role, alone, or in combination with the ctTDV staging system in personalising treatment for patient’s with right colon cancer.
Patients who underwent surgery at hospitals who perform CME surgery and hospitals who perform Non-CME surgery with curative intent colon cancer between January 2010 and December 2019 are eligible. As DRIVEN is a retrospective study, there are no time dependent schedules for CRF completion or tissue submission.